| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Biosimilars and biopharmaceuticals: what the nephrologists need to know--a position paper by the ERA-EDTA Council.
|
Nephrol Dial Transplant
|
2008
|
2.42
|
|
2
|
Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease.
|
Nephrol Dial Transplant
|
2008
|
2.41
|
|
3
|
Management of atrial fibrillation in chronic kidney disease: double trouble.
|
Am Heart J
|
2013
|
2.14
|
|
4
|
Immunogenicity of biopharmaceuticals.
|
Nephrol Dial Transplant
|
2006
|
1.74
|
|
5
|
Coronary artery calcification measured with electron-beam computerized tomography correlates poorly with coronary artery angiography in dialysis patients.
|
Am J Kidney Dis
|
2004
|
1.60
|
|
6
|
Serum sclerostin and adverse outcomes in nondialyzed chronic kidney disease patients.
|
J Clin Endocrinol Metab
|
2014
|
1.57
|
|
7
|
Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study design and baseline characteristics of the IMPACT SHPT study.
|
Nephrol Dial Transplant
|
2011
|
1.46
|
|
8
|
Negative outcome studies in end-stage renal disease: how dark are the storm clouds?
|
Nephrol Dial Transplant
|
2007
|
1.44
|
|
9
|
Extraordinary popular delusions and the madness of crowds: puncturing the epoetin bubble--lessons for the future.
|
Nephrol Dial Transplant
|
2010
|
1.40
|
|
10
|
Accelerating statistical research in drug safety.
|
Pharmacoepidemiol Drug Saf
|
2006
|
1.39
|
|
11
|
Use of phosphate-binding agents is associated with a lower risk of mortality.
|
Kidney Int
|
2013
|
1.35
|
|
12
|
Aortic pulse wave velocity and albuminuria in patients with type 2 diabetes.
|
J Am Soc Nephrol
|
2005
|
1.31
|
|
13
|
Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement.
|
Nephrol Dial Transplant
|
2013
|
1.28
|
|
14
|
Assessing glycemic control in patients with diabetes and end-stage renal failure.
|
Am J Kidney Dis
|
2003
|
1.19
|
|
15
|
Pulmonary hypertension in CKD.
|
Am J Kidney Dis
|
2012
|
1.19
|
|
16
|
Phosphate - the silent stealthy cardiorenal culprit in all stages of chronic kidney disease: a systematic review.
|
Blood Purif
|
2009
|
1.19
|
|
17
|
Calciphylaxis: calcific uremic arteriolopathy and the emerging role of sodium thiosulfate.
|
Int Urol Nephrol
|
2008
|
1.16
|
|
18
|
A review of safety, efficacy, and utilization of erythropoietin, darbepoetin, and peginesatide for patients with cancer or chronic kidney disease: a report from the Southern Network on Adverse Reactions (SONAR).
|
Semin Thromb Hemost
|
2012
|
1.05
|
|
19
|
Multimodal management of urolithiasis in renal transplantation.
|
BJU Int
|
2005
|
1.03
|
|
20
|
Mammalian target of rapamycin (mTOR) inhibitors: potential uses and a review of haematological adverse effects.
|
Drug Saf
|
2011
|
1.02
|
|
21
|
Monocyte subpopulations and cardiovascular risk in chronic kidney disease.
|
Nat Rev Nephrol
|
2012
|
1.02
|
|
22
|
Clinical usefulness of novel prognostic biomarkers in patients on hemodialysis.
|
Nat Rev Nephrol
|
2011
|
1.01
|
|
23
|
Anemia after renal transplantation.
|
Am J Kidney Dis
|
2006
|
1.01
|
|
24
|
Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study.
|
Nephrol Dial Transplant
|
2012
|
0.99
|
|
25
|
Serum vitamin D levels are independently associated with severity of coronary artery disease.
|
J Investig Med
|
2012
|
0.97
|
|
26
|
Magnesium in chronic kidney disease: challenges and opportunities.
|
Blood Purif
|
2010
|
0.96
|
|
27
|
Pregabalin versus gabapentin in the treatment of neuropathic pruritus in maintenance haemodialysis patients: a prospective, crossover study.
|
Nephrology (Carlton)
|
2012
|
0.95
|
|
28
|
Assessment of arterial stiffness for clinical and epidemiological studies: methodological considerations for validation and entry into the European Renal and Cardiovascular Medicine registry.
|
Nephrol Dial Transplant
|
2013
|
0.93
|
|
29
|
COSMOS: the dialysis scenario of CKD-MBD in Europe.
|
Nephrol Dial Transplant
|
2012
|
0.92
|
|
30
|
Maternal vitamin D status during pregnancy and bone-mineral content in offspring.
|
Lancet
|
2013
|
0.91
|
|
31
|
Influence of body mass index on the association of weight changes with mortality in hemodialysis patients.
|
Clin J Am Soc Nephrol
|
2013
|
0.89
|
|
32
|
The relationship between chronic volume overload and elevated blood pressure in hemodialysis patients: use of bioimpedance provides a different perspective from echocardiography and biomarker methodologies.
|
Int Urol Nephrol
|
2010
|
0.89
|
|
33
|
Summary of the 5th edition of the Renal Association Clinical Practice Guidelines (2009-2012).
|
Nephron Clin Pract
|
2011
|
0.88
|
|
34
|
Allopurinol, uric acid, and oxidative stress in cardiorenal disease.
|
Int Urol Nephrol
|
2011
|
0.88
|
|
35
|
An economic evaluation of sevelamer in patients new to dialysis.
|
Curr Med Res Opin
|
2008
|
0.88
|
|
36
|
Monocyte count/HDL cholesterol ratio and cardiovascular events in patients with chronic kidney disease.
|
Int Urol Nephrol
|
2014
|
0.87
|
|
37
|
Renal anemia of inflammation: the name is self-explanatory.
|
Blood Purif
|
2011
|
0.87
|
|
38
|
What counts in data mining?
|
Drug Saf
|
2006
|
0.85
|
|
39
|
Cost-effectiveness of lanthanum carbonate versus sevelamer hydrochloride for the treatment of hyperphosphatemia in patients with end-stage renal disease: a US payer perspective.
|
Value Health
|
2011
|
0.84
|
|
40
|
A pharmacoepidemiological study of the multi-level determinants, predictors, and clinical outcomes of biosimilar epoetin alfa for renal anaemia in haemodialysis patients: background and methodology of the MONITOR-CKD5 study.
|
Intern Emerg Med
|
2011
|
0.84
|
|
41
|
Sudden death in hemodialysis: an update.
|
Blood Purif
|
2010
|
0.84
|
|
42
|
Thrombotic micro-angiopathy with sirolimus-based immunosuppression: potentiation of calcineurin-inhibitor-induced endothelial damage?
|
Am J Transplant
|
2003
|
0.84
|
|
43
|
Determinants of vitamin D status in long-term renal transplant patients.
|
Clin Transplant
|
2012
|
0.83
|
|
44
|
Paricalcitol- or cinacalcet-centred therapy affects markers of bone mineral disease in patients with secondary hyperparathyroidism receiving haemodialysis: results of the IMPACT-SHPT study.
|
Nephrol Dial Transplant
|
2014
|
0.83
|
|
45
|
Statin treatment for dyslipidemia in chronic kidney disease and renal transplantation: a review of the evidence.
|
J Nephrol
|
2009
|
0.81
|
|
46
|
The management of end-stage heart failure and reducing the risk of cardiorenal syndrome.
|
Clin Med
|
2013
|
0.81
|
|
47
|
Septic arthritis due to extended spectrum beta lactamase producing Klebsiella pneumoniae.
|
Joint Bone Spine
|
2007
|
0.81
|
|
48
|
Association of anaemia in primary care patients with chronic kidney disease: cross sectional study of quality improvement in chronic kidney disease (QICKD) trial data.
|
BMC Nephrol
|
2013
|
0.81
|
|
49
|
Association of serum calcitonin with coronary artery disease in individuals with and without chronic kidney disease.
|
Int Urol Nephrol
|
2011
|
0.81
|
|
50
|
Jupiter or Aurora? Micro-inflammation and dyslipidaemia: twin targets for statin therapy in CKD.
|
Int Urol Nephrol
|
2009
|
0.80
|
|
51
|
Cerivastatin monotherapy-induced muscle weakness, rhabdomyolysis and acute renal failure.
|
Int J Cardiol
|
2003
|
0.80
|
|
52
|
Anaemia, microcytosis and sirolimus--is iron the missing link?
|
Nephrol Dial Transplant
|
2010
|
0.80
|
|
53
|
Ambulatory blood pressure monitoring in hemodialysis patients: a critique and literature review.
|
Semin Dial
|
2004
|
0.80
|
|
54
|
Glomerular filtration rate in prospective living kidney donors.
|
Int Urol Nephrol
|
2013
|
0.79
|
|
55
|
The prevalence of electrocardiographic early repolarization in an adult cohort with chronic kidney disease and its impact upon all-cause mortality and progression to dialysis.
|
Front Physiol
|
2013
|
0.79
|
|
56
|
Studies on the relationship between electrogustometry and sour taste perception.
|
Auris Nasus Larynx
|
2007
|
0.79
|
|
57
|
The effects of vitamin D therapy on left ventricular structure and function - are these the underlying explanations for improved CKD patient survival?
|
Nephron Clin Pract
|
2010
|
0.79
|
|
58
|
Stimulating erythropoiesis: future perspectives.
|
Kidney Blood Press Res
|
2008
|
0.79
|
|
59
|
Long-term safety and efficacy of renin-angiotensin blockade in atherosclerotic renal artery stenosis.
|
Int Urol Nephrol
|
2011
|
0.79
|
|
60
|
Renal failure with granulomatous interstitial nephritis and diffuse leukemic renal infiltration in chronic lymphocytic leukemia.
|
Ren Fail
|
2007
|
0.79
|
|
61
|
Sudden cardiac death in patients with chronic kidney disease: prevention is the sine qua non.
|
Kidney Blood Press Res
|
2011
|
0.78
|
|
62
|
Low-dose mycophenolate mofetil is an effective and safe treatment to permit phased reduction in calcineurin inhibitors in chronic allograft nephropathy.
|
Transplantation
|
2005
|
0.78
|
|
63
|
The use of echocardiography in observational clinical trials: the EURECA-m registry.
|
Nephrol Dial Transplant
|
2012
|
0.78
|
|
64
|
Renin angiotensin aldosterone system (RAAS) inhibitors in the prevention of early renal disease in diabetes.
|
F1000 Med Rep
|
2010
|
0.78
|
|
65
|
Vitamin K status in chronic kidney disease: a report of a study and a mini-review.
|
Int Urol Nephrol
|
2013
|
0.78
|
|
66
|
Regression of vascular calcification in chronic kidney disease - feasible or fantasy? a review of the clinical evidence.
|
Br J Clin Pharmacol
|
2013
|
0.78
|
|
67
|
Routine bioimpedance-derived volume assessment for all hypertensives: a new paradigm.
|
Am J Nephrol
|
2014
|
0.78
|
|
68
|
Identifying and managing nephrotic syndrome in adults.
|
Practitioner
|
2008
|
0.78
|
|
69
|
Time to Reconsider Evidence for Anaemia Treatment (TREAT) = Essential Safety Arguments (ESA).
|
Nephrol Dial Transplant
|
2010
|
0.77
|
|
70
|
How important and how treatable is vascular stiffness as a cardiovascular risk factor in renal failure?
|
Nephrol Dial Transplant
|
2002
|
0.77
|
|
71
|
Erythropoiesis-stimulating agents (ESA) for preventing the progression of chronic kidney disease: a meta-analysis of 19 studies.
|
Am J Nephrol
|
2014
|
0.77
|
|
72
|
Statins and kidney disease: is the study of heart and renal protection at the cutting edge of evidence?
|
Curr Opin Cardiol
|
2012
|
0.77
|
|
73
|
Thrombophilia of nephrotic syndrome in adults.
|
Clin Adv Hematol Oncol
|
2009
|
0.77
|
|
74
|
The battle against obesity: lessons from tobacco.
|
Lancet
|
2011
|
0.77
|
|
75
|
Guidelines for submitting adverse event reports for publication.
|
Therapie
|
2009
|
0.77
|
|
76
|
Post-transplantation anaemia in adult and paediatric renal allograft recipients-Guy's Hospital experience.
|
Nephrol Dial Transplant
|
2006
|
0.76
|
|
77
|
Drug interaction in a renal transplant patient: cyclosporin-Neoral and orlistat.
|
Am J Kidney Dis
|
2003
|
0.76
|
|
78
|
Blood pressure control in CKD stage 5D patients--are we more or less certain what to do in 2009?
|
Nephrol Dial Transplant
|
2009
|
0.76
|
|
79
|
Ambulatory blood pressure monitoring: an essential tool for blood pressure assessment in uraemic patients.
|
Nephrol Dial Transplant
|
2002
|
0.76
|
|
80
|
Adaptation and implementation of the "Kidney Disease: Improving Global Outcomes (KDIGO)" guidelines for evaluation and management of mineral and bone disorders in chronic kidney disease for practice in the Middle East countries.
|
Saudi J Kidney Dis Transpl
|
2014
|
0.76
|
|
81
|
Mineral and bone disorder after renal transplantation: a review.
|
Int Urol Nephrol
|
2007
|
0.76
|
|
82
|
(18)F-fluoride positron emission tomography measurements of regional bone formation in hemodialysis patients with suspected adynamic bone disease.
|
Calcif Tissue Int
|
2013
|
0.76
|
|
83
|
Methionine AminoPeptidase Type-2 Inhibitors Targeting Angiogenesis.
|
Curr Top Med Chem
|
2016
|
0.76
|
|
84
|
Mycophenolate mofetil treatment following renal transplantation decreases GTP concentrations in mononuclear leucocytes.
|
Clin Sci (Lond)
|
2004
|
0.76
|
|
85
|
Best approaches in the battle against Globesity? Learning lessons from our experience tackling HIV-AIDS and tobacco smoking.
|
JRSM Short Rep
|
2012
|
0.75
|
|
86
|
A new approach to authorship: institutions must decide.
|
J R Soc Med
|
2012
|
0.75
|
|
87
|
Risk-based individualisation of target haemoglobin in haemodialysis patients with renal anaemia in the post-TREAT era: theoretical attitudes versus actual practice patterns (MONITOR-CKD5 study).
|
Int Urol Nephrol
|
2015
|
0.75
|
|
88
|
Detection of bowel cancer in kidney transplant recipients.
|
BMJ
|
2012
|
0.75
|
|
89
|
Chronic kidney disease, anemia, and epoetin.
|
N Engl J Med
|
2007
|
0.75
|
|
90
|
Phosphodiesterase type 5 inhibitors and kidney disease.
|
Int Urol Nephrol
|
2015
|
0.75
|
|
91
|
Post-transplant lymphoproliferative disorder (PTLD) presenting as painful lymphocele 12 years after a cadaveric renal transplant.
|
Int Urol Nephrol
|
2008
|
0.75
|
|
92
|
Tackling the QOF2 indicators for CKD.
|
Practitioner
|
2007
|
0.75
|
|
93
|
Factors affecting circulating mRNA for nephrin.
|
Clin Chem
|
2005
|
0.75
|
|
94
|
Biosimilars: uncharted territory.
|
J Nephrol
|
2007
|
0.75
|
|
95
|
Differential effects of T-cell activation on gastric and small bowel permeability in alcohol-consuming mice.
|
Alcohol Clin Exp Res
|
2002
|
0.75
|
|
96
|
Case report: making the CONN-ection: two cases of persistent hypertension and hypokalaemia following renal transplantation.
|
Int Urol Nephrol
|
2011
|
0.75
|
|
97
|
Direct renin inhibitors: ONTARGET for success?
|
Int Urol Nephrol
|
2009
|
0.75
|
|
98
|
Early detection of CKD will reduce heart disease risk.
|
Practitioner
|
2009
|
0.75
|
|
99
|
Novel Multivalent Wound-Healing Ointment Provides Bioburden Control and Moisture Management: A Retrospective Registry Data Analysis.
|
Adv Skin Wound Care
|
2016
|
0.75
|
|
100
|
Renal Association Clinical Practice Guideline on cardiovascular disease in CKD.
|
Nephron Clin Pract
|
2011
|
0.75
|
|
101
|
The Janus faces of ESAs: caveat Chimaera!
|
Int Urol Nephrol
|
2012
|
0.75
|
|
102
|
Comparison of estimated GFR and measured GFR in prospective living kidney donors.
|
Int Urol Nephrol
|
2014
|
0.75
|
|
103
|
Inflammation and coronary calcification in renal patients--factors that may explain increased cardiovascular risk, and poorer results of coronary interventions?
|
J Nephrol
|
2004
|
0.75
|
|
104
|
New immunosuppressive therapies in renal transplantation: monoclonal antibodies.
|
J Nephrol
|
2005
|
0.75
|
|
105
|
Serious interaction between tacrolimus FK506 and chloramphenicol in a kidney-pancreas transplant recipient.
|
Transpl Int
|
2003
|
0.75
|